CTLA4 and neoplasm: This serves as the rationale for using anti-CTLA-4 antibodies such as ipilimumab and tremelimumab that block this interaction as a means of cancer immunotherapy, aiming to enhance anti-tumor immune responses (Figure 1B) (24).